ZA200707896B - Benzazole derivatives, compositions, and methods of use as B-secretase inhibitors - Google Patents

Benzazole derivatives, compositions, and methods of use as B-secretase inhibitors

Info

Publication number
ZA200707896B
ZA200707896B ZA200707896A ZA200707896A ZA200707896B ZA 200707896 B ZA200707896 B ZA 200707896B ZA 200707896 A ZA200707896 A ZA 200707896A ZA 200707896 A ZA200707896 A ZA 200707896A ZA 200707896 B ZA200707896 B ZA 200707896B
Authority
ZA
South Africa
Prior art keywords
compositions
methods
secretase inhibitors
benzazole derivatives
benzazole
Prior art date
Application number
ZA200707896A
Other languages
English (en)
Inventor
Mjalli Adnan Mm
Jones David
Gohimmukkula Devi Reddy
Huang Guoxiang
Zhu Jeff
Rao Mohan
Robert C Andrews
Ren Tan
Original Assignee
High Point Pharma Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by High Point Pharma Llc filed Critical High Point Pharma Llc
Publication of ZA200707896B publication Critical patent/ZA200707896B/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/24—Benzimidazoles; Hydrogenated benzimidazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
    • C07D235/30—Nitrogen atoms not forming part of a nitro radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
    • C07D407/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Pain & Pain Management (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
ZA200707896A 2005-03-14 2006-03-14 Benzazole derivatives, compositions, and methods of use as B-secretase inhibitors ZA200707896B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US66134905P 2005-03-14 2005-03-14

Publications (1)

Publication Number Publication Date
ZA200707896B true ZA200707896B (en) 2009-07-29

Family

ID=36694148

Family Applications (2)

Application Number Title Priority Date Filing Date
ZA200707896A ZA200707896B (en) 2005-03-14 2006-03-14 Benzazole derivatives, compositions, and methods of use as B-secretase inhibitors
ZA2009/03300A ZA200903300B (en) 2005-03-14 2009-05-13 Benzazole derivatives, compositions, and methods of use as b-secretase inhibitors

Family Applications After (1)

Application Number Title Priority Date Filing Date
ZA2009/03300A ZA200903300B (en) 2005-03-14 2009-05-13 Benzazole derivatives, compositions, and methods of use as b-secretase inhibitors

Country Status (13)

Country Link
US (4) US20060223849A1 (https=)
EP (2) EP1863771B1 (https=)
JP (2) JP5066514B2 (https=)
CN (1) CN101142194B (https=)
AU (1) AU2006223070B2 (https=)
BR (1) BRPI0608581A2 (https=)
CA (1) CA2600570C (https=)
ES (1) ES2400287T3 (https=)
IL (2) IL185541A (https=)
MX (1) MX2007011234A (https=)
NZ (1) NZ561029A (https=)
WO (1) WO2006099379A2 (https=)
ZA (2) ZA200707896B (https=)

Families Citing this family (106)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060223849A1 (en) * 2005-03-14 2006-10-05 Mjalli Adnan M Benzazole derivatives, compositions, and methods of use as beta-secretase inhibitors
TWI370820B (en) 2005-04-27 2012-08-21 Takeda Pharmaceutical Fused heterocyclic compounds
CA2628074C (en) 2005-10-25 2014-01-14 Shionogi & Co., Ltd. Aminodihydrothiazine derivative
CN101379060B (zh) * 2006-02-10 2012-05-23 转化技术制药公司 作为Aurora激酶抑制剂的苯并唑系衍生物、组合物和使用方法
CA2641880C (en) 2006-02-10 2014-09-09 Summit Corporation Plc Treatment of duchenne muscular dystrophy
CA2645551C (en) 2006-03-16 2016-06-28 Renovis, Inc. Bicycloheteroaryl compounds as p2x7 modulators and uses thereof
EP2010520B1 (en) * 2006-04-20 2012-09-12 Pfizer Products Inc. Heterobicyclic amides for the prevention and treatment of glucokinase-mediated diseases
TW200815349A (en) 2006-06-22 2008-04-01 Astrazeneca Ab New compounds
AR063311A1 (es) * 2006-10-18 2009-01-21 Novartis Ag Compuestos organicos
US20100056515A1 (en) * 2006-10-25 2010-03-04 Kazuyoshi Aso Benzimidazole compounds
JP2010514672A (ja) 2006-12-29 2010-05-06 武田薬品工業株式会社 Ｃｒｆアンタゴニスト活性を有する縮合複素環化合物
US8653067B2 (en) 2007-04-24 2014-02-18 Shionogi & Co., Ltd. Pharmaceutical composition for treating Alzheimer's disease
JP5383484B2 (ja) 2007-04-24 2014-01-08 塩野義製薬株式会社 環式基で置換されたアミノジヒドロチアジン誘導体
CA2685266C (en) * 2007-04-27 2014-01-28 Purdue Pharma L.P. Trpv1 antagonists and uses thereof for the treatment of prevention of pain, ui and ulcer, ibd, or ibs in an animal
TW200902499A (en) 2007-05-15 2009-01-16 Astrazeneca Ab New compounds
CA2685540C (en) * 2007-08-03 2018-10-16 Graham Michael Wynne Drug combinations for the treatment of duchenne muscular dystrophy
GB0715937D0 (en) * 2007-08-15 2007-09-26 Vastox Plc Method of treatment og duchenne muscular dystrophy
NZ585298A (en) 2007-11-16 2012-08-31 Rigel Pharmaceuticals Inc Carboxamide, sulfonamide and amine compounds for metabolic disorders
EP2231666B1 (en) 2007-12-12 2015-07-29 Rigel Pharmaceuticals, Inc. Carboxamide, sulfonamide and amine compounds for metabolic disorders
TWI498115B (zh) * 2007-12-27 2015-09-01 Daiichi Sankyo Co Ltd 咪唑羰基化合物
WO2009083553A1 (en) * 2007-12-31 2009-07-09 Rheoscience A/S Azine compounds as glucokinase activators
FR2925904B1 (fr) * 2008-01-02 2010-01-01 Sanofi Aventis DERIVES DE N-HETEROCYCLIQUE-6-HETEROCYCLIQUE-IMIDAZO°1,2-a! PYRIDINE-2-CARBOXAMIDES, LEUR PREPARATION ET LEUR APPLICATION EN THERAPEUTIQUE
BRPI0911681B8 (pt) 2008-04-23 2021-05-25 Rigel Pharmaceuticals Inc composto, composição farmacêutica, e, método para ativar a via de proteína quinase ativada por 5'-amp em uma célula in vitro
DE102008022221A1 (de) 2008-05-06 2009-11-12 Universität des Saarlandes Inhibitoren der humanen Aldosteronsynthase CYP11B2
KR101324426B1 (ko) 2008-06-13 2013-10-31 시오노기세야쿠 가부시키가이샤 β 세크레타제 저해 작용을 갖는 황 함유 복소환 유도체
CA2725481A1 (en) 2008-06-18 2009-12-23 Pfizer Limited Nicotinamide derivatives
CA2729128C (en) * 2008-07-03 2016-05-31 Sirtris Pharmaceuticals, Inc. Benzimidazoles and related analogs as sirtuin modulators
JP5693452B2 (ja) * 2008-08-04 2015-04-01 シーエイチディーアイ ファウンデーション，インコーポレーテッド 特定のキヌレニン−３−モノオキシゲナーゼインヒビター、医薬組成物およびそれらの使用方法
US8193363B2 (en) * 2008-08-29 2012-06-05 Astrazeneca Ab Compounds suitable as precursors to compounds that are useful for imaging amyloid deposits
UY32138A (es) * 2008-09-25 2010-04-30 Boehringer Ingelheim Int Amidas sustituidas del ácido 2-(2,6-dicloro-fenilamino)-6-fluoro-1-metil-1h-bencimidazol-5-carboxílico y sus sales farmacéuticamente aceptables
US8394969B2 (en) 2008-09-26 2013-03-12 Merck Sharp & Dohme Corp. Cyclic benzimidazole derivatives useful as anti-diabetic agents
EP2348857B1 (en) 2008-10-22 2016-02-24 Merck Sharp & Dohme Corp. Novel cyclic benzimidazole derivatives useful anti-diabetic agents
CN102186841A (zh) 2008-10-22 2011-09-14 盐野义制药株式会社 具有bace1抑制活性的2-氨基嘧啶-4-酮及2-氨基吡啶衍生物
EP2352374B1 (en) 2008-10-29 2014-09-24 Merck Sharp & Dohme Corp. Novel cyclic benzimidazole derivatives useful anti-diabetic agents
US8329914B2 (en) 2008-10-31 2012-12-11 Merck Sharp & Dohme Corp Cyclic benzimidazole derivatives useful as anti-diabetic agents
TW201020244A (en) 2008-11-14 2010-06-01 Astrazeneca Ab New compounds
CN101619058A (zh) * 2009-01-08 2010-01-06 上海交通大学 一种苯并咪唑-4-酰胺型衍生物
US20100278835A1 (en) * 2009-03-10 2010-11-04 Astrazeneca Uk Limited Novel compounds 660
MX2011010218A (es) 2009-04-02 2011-10-10 Merck Patent Gmbh Inhibidores de autotaxina.
JP2012525389A (ja) * 2009-04-27 2012-10-22 ハイ ポイント ファーマシューティカルズ，リミティド ライアビリティ カンパニー 置換イソキノリン誘導体、医薬組成物、及びβ−セクレターゼ阻害剤としての使用方法
AU2010241929A1 (en) * 2009-04-27 2011-10-06 High Point Pharmaceuticals, Llc Substituted imidazo[1,2-a]pyridine derivatives, pharmaceutical compositions, and methods of use as beta-secretase inhibitors
SG176009A1 (en) * 2009-05-28 2011-12-29 Novartis Ag Substituted aminopropionic derivatives as neprilysin inhibitors
EP2281824A1 (en) 2009-08-07 2011-02-09 Noscira, S.A. Furan-imidazolone derivatives, for the treatment of cognitive, neurodegenerative or neuronal diseases or disorders
AU2010287976A1 (en) * 2009-08-31 2012-03-29 Ihara Chemical Industry Co., Ltd. Process for preparation of pyrimidinylacetonitrile derivatives and intermediates for synthesis thereof
AU2010289353B2 (en) * 2009-09-03 2016-12-08 Allergan, Inc. Compounds as tyrosine kinase modulators
US9340555B2 (en) 2009-09-03 2016-05-17 Allergan, Inc. Compounds as tyrosine kinase modulators
US8541404B2 (en) 2009-11-09 2013-09-24 Elexopharm Gmbh Inhibitors of the human aldosterone synthase CYP11B2
MX2012006491A (es) 2009-12-11 2012-07-03 Shionogi & Co Derivados de oxazina.
WO2011074658A1 (ja) 2009-12-18 2011-06-23 田辺三菱製薬株式会社 新規抗血小板薬
EP2523949B1 (en) 2010-01-15 2014-08-20 Janssen Pharmaceuticals Inc. Novel substituted triazole derivatives as gamma secretase modulators
CA2787365A1 (en) 2010-01-25 2011-07-28 Chdi Foundation, Inc. Certain kynurenine-3-monooxygenase inhibitors, pharmaceutical compositions, and methods of use thereof
JP2013520502A (ja) 2010-02-25 2013-06-06 メルク・シャープ・エンド・ドーム・コーポレイション 有用な抗糖尿病薬である新規な環状ベンズイミダゾール誘導体
EP2549874A4 (en) * 2010-03-23 2013-10-02 High Point Pharmaceuticals Llc SUBSTITUTED IMIDAZOLE [1,2-B] PYRIDAZINE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS, AND METHODS OF USE AS BETA-SECRETASE INHIBITORS
SG10201505997TA (en) 2010-08-05 2015-09-29 Amgen Inc Benzimidazole And Azabenzimidazole Compounds That Inhibit Anaplastic Lymphoma Kinase
EP2634188A4 (en) 2010-10-29 2014-05-07 Shionogi & Co FUSIONED AMINODIHYDROPYRIMIDINE DERIVATIVE
JP5816630B2 (ja) 2010-10-29 2015-11-18 塩野義製薬株式会社 ナフチリジン誘導体
EP2643299B1 (en) 2010-11-22 2016-06-22 Noscira, S.A. Bipyridine sulfonamide derivatives for the treatment of neurodegenerative diseases or conditions
US8883779B2 (en) 2011-04-26 2014-11-11 Shinogi & Co., Ltd. Oxazine derivatives and a pharmaceutical composition for inhibiting BACE1 containing them
PE20141531A1 (es) 2011-06-22 2014-10-23 Purdue Pharma Lp Antagonistas de trpv1 que incluyen sustituyentes dihidroxi y sus usos
TWI567079B (zh) 2011-07-15 2017-01-21 健生醫藥公司 作為伽瑪分泌酶調節劑之新穎的經取代的吲哚衍生物
PH12014500326B1 (en) 2011-08-18 2018-01-10 Nippon Shinyaku Co Ltd Heterocyclic derivative and pharmaceutical drug
KR20140072037A (ko) 2011-08-30 2014-06-12 씨에이치디아이 파운데이션, 인코포레이티드 키뉴레닌-3-모노옥시게나제 억제제, 약학적 조성물 및 이의 사용 방법
SI2750677T1 (sl) 2011-08-30 2017-10-30 Chdi Foundation, Inc. Inhibitorji kinurenin-3-monooksigenaze, farmacevtski sestavki in postopki njihove uporabe
EP3366685A1 (en) * 2012-01-09 2018-08-29 X-Chem, Inc. Tryptoline derivatives having kinase inhibitory activity and uses thereof
WO2013104577A1 (en) 2012-01-11 2013-07-18 Acesion Pharma Aps Benzimidazolyl-acetamide derivatives useful as potassium channel modulators
US9056874B2 (en) 2012-05-04 2015-06-16 Novartis Ag Complement pathway modulators and uses thereof
NZ702611A (en) 2012-05-16 2016-10-28 Cellzome Ltd Substituted 3, 4 - dihydro - 2h - pyrido [1, 2 -a] pyrazine - 1, 6 - dione derivatives useful for the treatment of (inter alia) alzheimer’s disease
CN103772376B (zh) * 2012-10-24 2017-01-11 中国医学科学院医药生物技术研究所 取代的苯并-1,3-杂唑类化合物、其制备方法及用途
EP2912035A4 (en) 2012-10-24 2016-06-15 Shionogi & Co DERIVATIVES OF DIHYDROOXAZINE OR OXAZEPINE HAVING BACE1 INHIBITING ACTIVITY
AU2013366668B2 (en) 2012-12-20 2017-07-20 Janssen Pharmaceutica Nv Novel tricyclic 3,4-dihydro-2H-pyrido[1,2-alpha]pyrazine -1,6-dione derivatives as gamma secretase modulators
ES2612215T3 (es) 2013-01-17 2017-05-12 Janssen Pharmaceutica, N.V. Novedosos derivados de pirido-piperazinona sustituidos como moduladores de gamma secretasa
US9475806B2 (en) 2013-03-14 2016-10-25 Novartis Ag Complement factor B inhibitors and uses there of
SI3010503T1 (sl) * 2013-06-21 2020-07-31 Zenith Epigenetics Ltd. Novi biciklični inhibitorji bromodomene
JP6461118B2 (ja) 2013-06-21 2019-01-30 ゼニス・エピジェネティクス・リミテッドＺｅｎｉｔｈ Ｅｐｉｇｅｎｅｔｉｃｓ Ｌｔｄ． ブロモドメイン阻害剤としての新規の置換された二環式化合物
JP6542212B2 (ja) 2013-07-31 2019-07-10 ゼニス・エピジェネティクス・リミテッドＺｅｎｉｔｈ Ｅｐｉｇｅｎｅｔｉｃｓ Ｌｔｄ． ブロモドメイン阻害剤としての新規キナゾリノン
CN105849090A (zh) 2013-10-30 2016-08-10 诺华股份有限公司 2-苄基-苯并咪唑补体因子b抑制剂及其用途
AU2014353150A1 (en) 2013-11-19 2016-07-07 Vanderbilt University Substituted imidazopyridine and triazolopyridine compounds as negative allosteric modulators of mGluR5
US10562897B2 (en) 2014-01-16 2020-02-18 Janssen Pharmaceutica Nv Substituted 3,4-dihydro-2H-pyrido[1,2-a]pyrazine-1,6-diones as gamma secretase modulators
EA031655B1 (ru) 2014-02-11 2019-02-28 Байер Фарма Акциенгезельшафт Бензимидазол-2-амины в качестве ингибиторов midhi
US9951027B2 (en) 2014-02-11 2018-04-24 Bayer Pharma Aktiengesellschaft Benzimidazol-2-amines as MIDH1 inhibitors
AU2015289492B2 (en) 2014-07-17 2020-02-20 Chdi Foundation, Inc. Methods and compositions for treating HIV-related disorders
GB201415569D0 (en) * 2014-09-03 2014-10-15 C4X Discovery Ltd Therapeutic Compounds
WO2016062677A1 (en) 2014-10-23 2016-04-28 Bayer Pharma Aktiengesellschaft Benzimidazol-2-amines as midh1 inhibitors
JP6672288B2 (ja) 2014-10-23 2020-03-25 バイエル・ファルマ・アクティエンゲゼルシャフト 腫瘍の治療のためのｍｉｄｈ１阻害剤としての１−シクロヘキシル−２−フェニルアミノベンゾイミダゾール
US10710992B2 (en) 2014-12-01 2020-07-14 Zenith Epigenetics Ltd. Substituted pyridinones as bromodomain inhibitors
WO2016092375A1 (en) 2014-12-11 2016-06-16 Zenith Epigenetics Corp. Substituted heterocycles as bromodomain inhibitors
CA2966450A1 (en) 2014-12-17 2016-06-23 Olesya KHARENKO Inhibitors of bromodomains
EP3303302B1 (en) 2015-06-08 2019-03-20 Bayer Pharma Aktiengesellschaft N-menthylbenzimidazoles as midh1 inhibitors
JP6824954B2 (ja) 2015-07-16 2021-02-03 ドイチェス クレープスフォルシュングスツェントルム シュティフトゥング デス エッフェントリッヒェン レヒツ ｍＩＤＨ１阻害剤としての５−ヒドロキシアルキルベンズイミダゾール
BR112018003812B1 (pt) * 2015-09-18 2024-04-30 Merck Patent Gmbh Compostos de heteroarila como inibidores de irak, seu uso, composição farmacêutica, e kit
CN108602776B (zh) * 2015-09-18 2021-12-03 默克专利有限公司 用作irak抑制剂的杂芳基化合物及其用途
AU2016371598B2 (en) * 2015-12-15 2021-05-13 The Board Of Trustees Of The Leland Stanford Junior University Method for preventing and/or treating aging-associated cognitive impairment and neuroinflammation
EP3390387B1 (en) 2015-12-18 2021-11-17 Bayer Pharma Aktiengesellschaft Heteroarylbenzimidazole compounds
GB201601703D0 (en) 2016-01-29 2016-03-16 C4X Discovery Ltd Therapeutic compounds
WO2017207534A1 (en) 2016-06-03 2017-12-07 Bayer Pharma Aktiengesellschaft Substituted heteroarylbenzimidazole compounds
GB201619694D0 (en) * 2016-11-22 2017-01-04 Entpr Therapeutics Ltd Compounds
CN106986809B (zh) * 2016-12-02 2020-03-24 广东省微生物研究所（广东省微生物分析检测中心） 一种5-溴-6-氯-3-吲哚辛酯的合成方法
TWI791593B (zh) * 2017-08-21 2023-02-11 德商馬克專利公司 做為腺苷受體拮抗劑之苯并咪唑衍生物
JP7313364B2 (ja) * 2018-02-21 2023-07-24 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Ｅｇｆｒ阻害剤としての新たなベンズイミダゾール化合物および誘導体
CN109400528B (zh) * 2018-12-18 2022-03-15 深圳科兴药业有限公司 一种可博美的合成方法
AU2020311940A1 (en) 2019-07-11 2022-02-03 ESCAPE Bio, Inc. Indazoles and azaindazoles as LRRK2 inhibitors
US12227475B2 (en) * 2021-04-27 2025-02-18 X-Biotix Therapeutics, Inc. Aza-heterocyclyl carboxamide and related compounds and their use in treating medical conditions
US20240300939A1 (en) 2021-06-14 2024-09-12 Scorpion Therapeutics, Inc. Urea derivatives which can be used to treat cancer
CN113387959B (zh) * 2021-06-24 2023-05-05 烟台理工学院 一种噻吩并[3,2-c]吡啶-6-羧酸甲酯的合成方法
WO2024211836A2 (en) 2023-04-05 2024-10-10 Moma Therapeutics, Inc. Semi-saturated bicyclic derivatives and related uses
AU2024254066A1 (en) * 2023-04-05 2025-10-16 Moma Therapeutics, Inc. Biaryl derivatives and related uses

Family Cites Families (84)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3401173A (en) * 1966-04-05 1968-09-10 Smith Kline French Lab Heterocyclic acylaminobenzimidazoles
US3336191A (en) * 1966-03-11 1967-08-15 Smith Kline French Lab Anthelmintic 2-amidobenzimidazoles
GB1122957A (en) 1965-06-07 1968-08-07 Smith Kline French Lab Substituted benzimidazoles and anthelmintic compositions containing them
US5552426A (en) * 1994-04-29 1996-09-03 Eli Lilly And Company Methods for treating a physiological disorder associated with β-amyloid peptide
US5744346A (en) * 1995-06-07 1998-04-28 Athena Neurosciences, Inc. β-secretase
JPH11507538A (ja) * 1995-06-07 1999-07-06 アテナ ニューロサイエンシズ インコーポレイティド β−セクレターゼ、β−セクレターゼに対する抗体、及びβ−セクレターゼ阻害を検出するためのアッセイ
US6329163B1 (en) * 1995-06-07 2001-12-11 Elan Pharmaceuticals, Inc. Assays for detecting β-secretase inhibition
GB9600142D0 (en) * 1996-01-05 1996-03-06 Wellcome Found Chemical compounds
JP4373497B2 (ja) * 1996-06-19 2009-11-25 ローン−プーラン・ロレ・リミテツド 置換されたアザビシクロ化合物、ならびにｔｎｆおよびサイクリックａｍｐホスホジエステラーゼ産生の阻害剤としてのそれらの使用
ES2200163T3 (es) * 1996-11-15 2004-03-01 Darwin Discovery Limited Aril-carboxamidas biciclicas y su utilizacion terapeutica.
AUPO395396A0 (en) * 1996-12-02 1997-01-02 Fujisawa Pharmaceutical Co., Ltd. Benzamide derivatives
ATE315394T1 (de) * 1997-11-10 2006-02-15 Bristol Myers Squibb Co Benzothiazole als protein tyrosin-kinase inhibitoren
US6699671B1 (en) * 1998-09-24 2004-03-02 Pharmacia & Upjohn Company Alzheimer's disease secretase, APP substrates therefor, and uses therefor
US20040234976A1 (en) * 1998-09-24 2004-11-25 Gurney Mark E. Alzheimer's disease secretase, app substrates therefor, and uses therefor
PL205294B1 (pl) * 1998-09-24 2010-03-31 Upjohn Co Izolowany lub oczyszczony polipeptyd, oczyszczony lub izolowany polinukleotyd, wektor, wektor ekspresyjny, komórka gospodarza, sposób wytwarzania polipeptydu, sposoby identyfikowania czynnika obniżającego, modulującego lub hamującego aktywność, zastosowanie takiego czynnika, izolowany kwas nukleinowy, obejmujący go wektor i ich zastosowanie, sposoby zmniejszania komórkowego wytwarzania beta amyloidu i zastosowanie antysensownego reagenta
US6245884B1 (en) * 1998-10-16 2001-06-12 Vivian Y. H. Hook Secretases related to alzheimer's dementia
TR200101498T2 (tr) * 1998-11-27 2001-11-21 Basf Aktiengesellschaft İkameli benzimidazoller ve parp inhibitörleri olarak kullanımları
GB2364059B (en) * 1999-02-10 2004-01-14 Elan Pharm Inc Beta-Secretase enzyme compositions and methods
DE19920936A1 (de) * 1999-05-07 2000-11-09 Basf Ag Heterozyklisch substituierte Benzimidazole, deren Herstellung und Anwendung
DK1194425T3 (da) * 1999-06-23 2005-11-21 Aventis Pharma Gmbh Substituerede benzimidazoler
CA2374610A1 (en) * 1999-06-28 2001-01-04 Jordan J. N. Tang Catalytically active recombinant memapsin and methods of use thereof
SI1196408T1 (en) * 1999-06-28 2005-02-28 Janssen Pharmaceutica N.V. Respiratory syncytial virus replication inhibitors
AU7314200A (en) * 1999-09-17 2001-04-24 Yamanouchi Pharmaceutical Co., Ltd. Benzimidazole derivatives
CA2384378C (en) 1999-10-06 2011-05-24 Boehringer Ingelheim Pharmaceuticals, Inc. Heterocyclic compounds useful as inhibitors of tyrosine kinases
US6506769B2 (en) * 1999-10-06 2003-01-14 Boehringer Ingelheim Pharmaceuticals, Inc. Heterocyclic compounds useful as inhibitors of tyrosine kinases
US20030092003A1 (en) * 1999-12-29 2003-05-15 Ribozyme Pharmaceuticals, Inc. Method and reagent for the treatment of Alzheimer's disease
US20030143708A1 (en) * 1999-12-29 2003-07-31 Blatt La Wrence Method and reagent for the treatment of alzheimer's disease
DE60124080T2 (de) * 2000-03-23 2007-03-01 Elan Pharmaceuticals, Inc., San Francisco Verbindungen und verfahren zur behandlung der alzheimerschen krankheit
CA2407088A1 (en) * 2000-05-19 2001-11-22 Takeda Chemical Industries, Ltd. Beta-secretase inhibitors
US6713276B2 (en) * 2000-06-28 2004-03-30 Scios, Inc. Modulation of Aβ levels by β-secretase BACE2
US6846813B2 (en) * 2000-06-30 2005-01-25 Pharmacia & Upjohn Company Compounds to treat alzheimer's disease
PE20020276A1 (es) * 2000-06-30 2002-04-06 Elan Pharm Inc COMPUESTOS DE AMINA SUSTITUIDA COMO INHIBIDORES DE ß-SECRETASA PARA EL TRATAMIENTO DE ALZHEIMER
CA2410898A1 (en) * 2000-07-19 2002-01-24 Pharmacia & Upjohn Company Substrates and assays for .beta.-secretase activity
WO2002014319A2 (en) 2000-08-11 2002-02-21 Boehringer Ingelheim Pharmaceuticals, Inc. Heterocyclic compounds useful as inhibitors of tyrosine kinases
WO2002025276A1 (en) * 2000-09-22 2002-03-28 Wyeth Crystal structure of bace and uses thereof
US20020157122A1 (en) * 2000-10-27 2002-10-24 Wong Philip C. Beta-secretase transgenic organisms, anti-beta-secretase antibodies, and methods of use thereof
JP2004517892A (ja) * 2000-12-13 2004-06-17 ワイス β−アミロイド産生の複素環スルホンアミド阻害剤
GB0101313D0 (en) * 2001-01-18 2001-02-28 Glaxo Group Ltd Assay
WO2002076926A1 (en) * 2001-02-02 2002-10-03 Schering Corporation 3,4-di-substituted cyclobutene-1, 2-diones as cxc chemokine receptor antagonists
EP1233021A3 (en) * 2001-02-20 2002-11-20 Pfizer Products Inc. An inhibitor of Beta amyloid cleavage enzyme
JP2004524843A (ja) * 2001-02-23 2004-08-19 イーラン ファーマスーティカルズ、インコーポレイテッド Ｂａｃｅ−１のトランスジェニックノックアウト
CN1235583C (zh) 2001-03-05 2006-01-11 特兰斯泰克制药公司 用作治疗剂的苯并咪唑衍生物
JP2004532826A (ja) * 2001-03-19 2004-10-28 スローン−ケッタリング インスティトゥート フォー カンサー リサーチ （ｓ，ｒ，ｒ）−（−）−アクチノニンおよびそのアナログの不斉合成、ならびにそれらの使用
US20040097547A1 (en) * 2001-04-16 2004-05-20 Taveras Arthur G. 3,4-Di-substituted cyclobutene-1,2-diones as CXC-chemokine receptor ligands
EP1389194A2 (en) * 2001-04-27 2004-02-18 Vertex Pharmaceuticals Incorporated Inhibitors of bace
FR2824825B1 (fr) * 2001-05-15 2005-05-06 Servier Lab Nouveaux derives d'alpha-amino-acides, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
US6562783B2 (en) * 2001-05-30 2003-05-13 Neurologic, Inc. Phosphinylmethyl and phosphorylmethyl succinic and glutauric acid analogs as β-secretase inhibitors
CA2451664A1 (en) * 2001-06-25 2003-01-03 Elan Pharmaceuticals, Inc. Use of bicyclo compounds for treating alzheimer's disease
US20030093356A1 (en) * 2001-07-06 2003-05-15 Assetsight, Inc. Method for issuing a derivative contract
MXPA04000328A (es) * 2001-07-10 2004-07-23 Pharmacia & Upjohn Comapny Derivados de alfa-hidroxiamida estatina para tratamiento de enfermedad de alzheimer.
US20030109559A1 (en) * 2001-07-11 2003-06-12 Andrea Gailunas N-(3-amino-2-hydroxy-propyl)substituted alkylamide compounds
CA2483959A1 (en) * 2001-08-28 2003-03-13 Elan Pharmaceuticals, Inc. Method for treating alzheimer's disease using quinaldoyl-amine derivatives of oxo- and hydroxy-substituted hydrocarbons
GB0123379D0 (en) * 2001-09-28 2001-11-21 Lorantis Ltd Modulators
US7132438B2 (en) * 2001-10-09 2006-11-07 Amgen Inc. Benzimidazole derivatives
ATE369854T1 (de) * 2001-10-19 2007-09-15 Ortho Mcneil Pharm Inc 2-phenyl benzimidazole und imidazo-[4,5]-pyridine als cds1/chk2-inhibitoren und adjuvantien in der chemotherapie oder strahlungstherapie zur behandlung von krebs
WO2003037860A2 (en) * 2001-10-30 2003-05-08 Conforma Therapeutics Corporation Purine analogs having hsp90-inhibiting activity
AU2002359376B2 (en) * 2001-11-08 2008-01-10 Elan Pharmaceuticals, Inc. N, N'-substituted-1,3-diamino-2-hydroxypropane derivatives
JP2005509003A (ja) * 2001-11-09 2005-04-07 ベーリンガー インゲルハイム ファーマシューティカルズ インコーポレイテッド タンパク質キナーゼインヒビターとして有用なベンゾイミダゾール化合物
US6620811B2 (en) * 2001-11-19 2003-09-16 Hoffmann-La Roche Inc. Isonicotin- and nicotinamide derivatives of benzothiazoles
CH698246B1 (de) * 2001-12-20 2009-06-30 Hoffmann La Roche Test zur Identifizierung von Inhibitoren von Beta-Sekretasen.
FR2833948B1 (fr) 2001-12-21 2004-02-06 Sod Conseils Rech Applic Nouveaux derives de benzimidazole et leur utilisation en tant que medicament
US7273743B2 (en) * 2002-02-21 2007-09-25 Elan Pharmaceuticals, Inc. Modified BACE
DE60325519D1 (de) * 2002-03-01 2009-02-12 Hoffmann La Roche Doppel-transgenisches, nicht-humanes Säugertiermodell für die Alzheimer Krankheit
DK1482931T3 (da) * 2002-03-05 2011-12-19 Transtech Pharma Inc Mono- og bicycliske azolderivater der inhiberer interaktionen af ligander med RAGE
US20040014194A1 (en) * 2002-03-27 2004-01-22 Schering Corporation Beta-secretase crystals and methods for preparing and using the same
CA2484261A1 (en) 2002-04-16 2003-10-23 Teijin Limited Piperidine derivatives having ccr3 antagonism
JP2005289816A (ja) * 2002-05-14 2005-10-20 Banyu Pharmaceut Co Ltd ベンズイミダゾール誘導体
US7049333B2 (en) * 2002-06-04 2006-05-23 Sanofi-Aventis Deutschland Gmbh Substituted thiophenes: compositions, processes of making, and uses in disease treatment and diagnosis
EP1572129A4 (en) * 2002-06-07 2007-03-28 Univ North Carolina AMIDINE DERIVATIVES FOR THE TREATMENT OF AMYLOIDOSE
PL374191A1 (en) 2002-06-13 2005-10-03 Vertex Pharmaceuticals Incorporated 2-ureido-6-heteroaryl-3h-benzoimidazole-4-carboxylic acid derivatives and related compounds as gyrase and/or topoisomerase iv inhibitors for the treatment of bacterial infections
US20040034078A1 (en) * 2002-06-14 2004-02-19 Agouron Pharmaceuticals, Inc. Benzimidazole inhibitors of poly(ADP-ribosyl) polymerase
US7115652B2 (en) * 2002-06-17 2006-10-03 Sunesis Pharmaceuticals, Inc. Aspartyl protease inhibitors
EP1388341A1 (en) * 2002-08-07 2004-02-11 Aventis Pharma Deutschland GmbH Acylamino-substituted heteroaromatic compounds and their use as pharmaceuticals
US7338956B2 (en) * 2002-08-07 2008-03-04 Sanofi-Aventis Deutschland Gmbh Acylamino-substituted heteroaromatic compounds and their use as pharmaceuticals
EP1539754A4 (en) * 2002-08-23 2009-02-25 Novartis Vaccines & Diagnostic BENZIMIDAZOCHINOLINONE AND ITS USE
CA2497979A1 (en) * 2002-09-06 2004-03-18 Elan Pharmaceuticals, Inc. 1, 3-diamino-2-hydroxypropane prodrug derivatives
UY27967A1 (es) * 2002-09-10 2004-05-31 Pfizer Acetil 2-hindroxi-1,3-diaminoalcanos
AU2003275225A1 (en) * 2002-09-20 2004-04-08 Genelabs Technologies, Inc. Novel aromatic compounds possessing antifungal or antibacterial activity
CA2507484A1 (en) * 2002-11-27 2004-06-17 Elan Pharmaceuticals, Inc. Substituted ureas and carbamates
WO2004084830A2 (en) * 2003-03-21 2004-10-07 Buck Institute Method for treating alzheimer’s dementia
WO2005070420A1 (en) * 2004-01-14 2005-08-04 Boehringer Ingelheim Pharmaceuticals, Inc. 1h-benzimidazol-2-yl-benzamide derivatives and related compounds as itk inhibitors (interleukin-2-inducible t cell kinase) for the treatment of inflammation, immunological and allergic disorders
US7470712B2 (en) * 2004-01-21 2008-12-30 Bristol-Myers Squibb Company Amino-benzazoles as P2Y1 receptor inhibitors
US20060223849A1 (en) * 2005-03-14 2006-10-05 Mjalli Adnan M Benzazole derivatives, compositions, and methods of use as beta-secretase inhibitors
CN101379060B (zh) * 2006-02-10 2012-05-23 转化技术制药公司 作为Aurora激酶抑制剂的苯并唑系衍生物、组合物和使用方法

Also Published As

Publication number Publication date
ES2400287T3 (es) 2013-04-08
JP5066514B2 (ja) 2012-11-07
EP1863771A2 (en) 2007-12-12
MX2007011234A (es) 2007-11-12
BRPI0608581A2 (pt) 2010-01-19
CN101142194B (zh) 2012-10-10
JP2008533151A (ja) 2008-08-21
WO2006099379A3 (en) 2007-06-14
US20060223849A1 (en) 2006-10-05
EP2457901A1 (en) 2012-05-30
HK1115752A1 (en) 2008-12-05
AU2006223070A1 (en) 2006-09-21
IL185541A (en) 2013-10-31
CN101142194A (zh) 2008-03-12
NZ561029A (en) 2011-03-31
US8946259B2 (en) 2015-02-03
IL222698A0 (en) 2012-12-31
US7893267B2 (en) 2011-02-22
US20140066477A1 (en) 2014-03-06
EP1863771B1 (en) 2012-11-07
US20090326006A1 (en) 2009-12-31
CA2600570A1 (en) 2006-09-21
CA2600570C (en) 2011-12-06
JP2012046541A (ja) 2012-03-08
US20110065713A1 (en) 2011-03-17
ZA200903300B (en) 2011-04-28
IL185541A0 (en) 2008-01-06
US8598353B2 (en) 2013-12-03
AU2006223070B2 (en) 2012-02-09
WO2006099379A2 (en) 2006-09-21

Similar Documents

Publication Publication Date Title
IL222698A0 (en) Benzazole derivatives, compositions, and methods of use as b- secretase inhibitors
IL192580A0 (en) Benzazole derivatives, compositions, and methods of use as aurora kinase inhibitors
IL176571A0 (en) Substituted azole derivatives, compositions, and methods of use
ZA200706345B (en) Amino-pyridines as inhibitors of ß-secretase
ZA200801822B (en) Pyrazine derivatives and use as p13k inhibitors
ZA200710951B (en) Piperidinyl-substituted isoquinolone derivatives as Rhokinase inhibitors
ZA200702394B (en) Indozolone derivatives as 11b-HSD1 inhibitors
IL198397A0 (en) Anilinopiperazine derivatives and methods of use thereof
IL191137A0 (en) Polycation-polyanion complexes, compositions and methods of use thereof
PL1940839T3 (pl) Pirydopirymidynonowe inhibitory PI3Kalfa
ZA200700181B (en) Aryl-pyridine derivatives as 11-beta-HSD1 inhibitors
HUS1500049I1 (hu) Protein kináz inhibitor vegyületek és készítmények
IL197161A (en) Derivatives 4- (n-azacycloalkyl) anilides Preparations containing and using them
AU2006343359A8 (en) Aminothiazole derivatives as human stearoyl-coa desaturase inhibitors
GB0700919D0 (en) Degradable compositions, apparatus comprising same, and methods of use
IL197724A0 (en) Compounds and compositions as protein kinase inhibitors
IL198315A0 (en) Compounds and compositions as protein kinase inhibitors
IL190885A0 (en) Immunogenic compositions and methods of use
SI2057153T1 (sl) (3-ril-piperazin-1-il) derivati 6,7-dialkoksikuinazolin, 6,7-dialkoksiftalazin in 6,7-dialkoksiizokuinolin
ZA200808431B (en) Fungicidal compositions and methods of using the same
ZA200905671B (en) Heterocyclic compounds, compositions comprising them and methods of their use
IL196000A0 (en) 2-arylindole derivatives as npges-i inhibitors
IL196594A0 (en) Derivatives of 4-trimethylammonium-3-aminobutyrate and 4-trimethylphosphonium-3-aminobutyrate as cpt-inhibitors
IL197504A0 (en) ISOSERINE DERIVATIVES AS INHIBITORS OF COAGULATION FACTOR IXa
EP2320738A4 (en) SUBSTITUTED AMINOTHIAZOL DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS THEREOF AND USE THEREOF